Advertisement

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Opening Session Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Feb
25
Today In Oncology
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer
MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy
Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma
Microplastics Found in 90 Percent of Prostate Cancer Samples
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo